Send to

Choose Destination
Circulation. 2018 Mar 20;137(12):1218-1220. doi: 10.1161/CIRCULATIONAHA.117.030117.

Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.

Author information

Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, United Kingdom (M.A.B.)
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.V.M.).


SGLT-2 inhibitor; canagliflozin; cardiovascular diseases; diabetes mellitus; empagliflozin; mortality; myocardial infarction

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center